Xilio Taps Former Tesaro Exec Martin Huber as Chief Medical Officer

Xilio Therapeutics has appointed Martin Huber to serve as its chief medical officer, the same position he held at Tesaro before its 2018 acquisition by GlaxoSmithKline (NYSE: [[ticker:GSK]]). His experience also includes roles at Merck (NYSE: [[ticker:MRK]]), Schering-Plough, Roche, and Rhone-Poulenc Rorer. Waltham, MA-based Xilio is developing antibody cancer drugs designed to activate their cancer-killing activity at the site of the tumor. In March, the biotech raised $100.5 million in Series B financing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.